Microangiopathic antiphospholipid syndrome (MAPS) in the course of undifferentiated connective tissue disease

Bożena Targońska-Stępniak; Ewa Wielosz; Maria Majdan

doi:10.20883/medical.e49

Authors

Bożena Targońska-Stępniak Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Poland
Ewa Wielosz Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Poland
Maria Majdan Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Poland

DOI:

https://doi.org/10.20883/medical.e49

Keywords:

microangiopathic antiphospholipid syndrome, connective tissue diseases, chronic kidney disease, anticoagulant treatment

Abstract

Introduction. The microangiopathic antiphospholipid syndrome (MAPS) is a subset of APS comprising those patients presenting with thrombotic microangiopathy and demonstrable antiphospholipid antibodies. Renal involvement occurs frequently in the course of MAPS with clinical symptoms of acute renal failure, hypertension, proteinuria and erythrocyturia.
Case report. The report presents the patient with MAPS confirmed by kidney biopsy in the course of undifferentiated connective tissue disease.
Conclusion. The authors emphasize the importance of effective anticoagulant treatment in order to inhibit thrombosis and renal damage in the course of MAPS.

Downloads

Download data is not yet available.

References

Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.

Majdan M. Zespół antyfosfolipidowy a choroba nerek. PolMerk Lek. 2010;28:341–4.

Asherson RA. New subsets of the antiphospholipid syndrome in. 2006: „PRE-APS” (probable APS) and microangiopathic antiphospholipid syndromes („MAPS”). Autoimmun Rev. 2006;6:76–80.

Tektonidou MG. Renal involvement in the antiphospholipid syndrome (APS)–APS Nephropathy. Clin Rev Allerg Immunol. 2009;36:131–40.

Majdan M. Nerki a zespół antyfosfolipidowy. Pol Arch Med Wewn. 2007;117(Supl):55–8.

Asherson RA, Cervera R. Microvascular and microangiopathic antiphospholipid-associated syndromes ("MAPS"): semantic or antisemantic? Autoimmun Rev. 2008;7:164–7.

Asherson RA, Pierangeli SS, Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis. 2007;66:429–32.

Asherson RA, Pierangeli S, Cervera R. Microangiopathic antiphospholipid-associated syndromes revisited new concepts relating to antiphospholipid antibodies and syndromes. J Rheumatol. 2007;34:1793–5.

Praprotnik S, Ferluga D, Vizjak A et al.: Microthrombotic/microangiopathic manifestations of the antiphospholipid syndrome. Clin Rev Allergy Immunol. 2009;36:109–25.

Salmon JE, Groot PG. Pathogenic role of antiphospholipid antibodies. Lupus. 2008;17:405–11.